drugset / Trial / NCT02468128

A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management

NCT02468128

Phase 2/3 Completed 221 enrolled Lumosa Therapeutics Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double blind, placebo-controlled, single dose study to assess the safety and efficacy of intramuscular sebacoyl dinalbuphine ester (SDE) for post-hemorrhoidectomy pain management.

Timeline

Start
2012-12
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dinalbuphine sebacate Small molecule 150 mg Intramuscular